Insurers revised their Shield plans from 1 April 2026, each with very different priorities. As a result, the best plan depends entirely on your individual needs. By carefully balancing medical benefits against long-term premium sustainability, we have identified the strongest options for each risk profile.
At a Glance: 2026 Comparison for Private Hospital Shield plan with riders
|
Plan and rider |
Annual Limit |
Non-CDL Cancer Drugs |
Co-payment |
Best For |
|
Enhanced IncomeShield Preferred + Essential Care |
$1.5M panel $1.5M non-panel |
$15,000/month |
7% panel 10% non-panel Cap $6,000 per year* |
Overall value & long-term affordability |
|
HSBC Life Shield Plan A + Enhanced Care II |
$2.5M panel $1M non-panel |
$30,000/month |
5% Cap $6,000 per year* |
Highest cancer ceiling |
|
Enhanced IncomeShield Preferred + Optima Care |
$1.5M panel $1.5M non-panel |
$15,000/month |
5% panel 8% non-panel Cap $6,000 per year* |
Families with young children |
|
Raffles Shield Private + Choice |
$1.5M panel $600K non-panel |
$5,000/year |
5% Cap $6,000 per year* |
Lowest premium option |
|
Singlife Shield Plan 1 + Health Plus Private |
$2M preferred $1M non-preferred |
$10,000/month |
5% Cap $6,000 per year* |
Rehabilitation & recovery support |
*The $6,000 cap applies only when treatment is provided by the insurer's panel/extended panel/preferred network or at a restructured hospital. Non-panel treatment carries uncapped co-payment.
The Hidden Cost: Your True Out-of-Pocket Maximum
The $6,000 co-payment cap is the headline number — but take note that this is not your absolute ceiling. It only applies when you stay within each insurer's panel network. The moment you choose a non-panel specialist:
- Co-payment becomes uncapped — you pay the full percentage on the entire bill
- For HSBC Life and Singlife, your annual policy limit also drops by 50–60% to $1million
- For Raffles Shield Private, your annual limit drops from $1.5 million to $600,000
Illustrative worst-case exposure on a $200,000 hospital bill at a non-panel specialist (including deductible):
|
Plan + Rider |
Co-payment % |
Estimated Out-of-Pocket |
|
Enhanced IncomeShield Preferred + Essential Care |
10% |
$23,150 (no cap) |
|
Enhanced IncomeShield Preferred + Optima Care |
8% |
$19,220 (no cap) |
|
HSBC Life Shield Plan A + Enhanced Care II |
5% |
$13,325, plus annual limit drops to $1 million |
|
Raffles Shield Private + Choice |
5% |
$13,325, plus annual limit drops to $600,000 |
|
Singlife Shield Plan 1 + Health Plus Private |
5% |
$13,325, plus annual limit drops to $1 million |
Data displayed above are indicative only for non-panel treatment at a private hospital for an individual age 80 and below. For illustration purposes only. Actual figures may vary depending on the specific IP and IP Rider selected.
Bottom line: For complex or chronic conditions where you may want a particular specialist, compare the potential costs of going to non-panel specialists before assuming you are fully covered.
If you are new to Integrated Shield Plan and are unsure which plan is right for you, here are our recommendations based on the new 2026 plan designs.
1. Best Overall Value: Enhanced IncomeShield Preferred + Essential Care rider
Ideal For: Those who wants a robust safety net against major illnesses while ensuring premiums remain sustainable for the next 20–30 years.
- High-End Protection, Mid-Tier Cost: You get the same elite medical access as top-tier plans, including $150,000 lifetime coverage for Cell, Tissue and Gene Therapies (CTGTP) treatments not on MOH’s CTGTP list and $15,000 per month for non-CDL cancer drugs. You will also receive robust cancer benefits of up to 23 times (5 times MSHL benefits from shield plan + 18 times MSHL benefits from rider) MediShield life (MSHL) benefits for outpatient cancer drug treatments.
- Freedom of Choice: Seeking treatment outside of Income’s panel? Your $1.5 million annual limit stays the same. Unlike other insurers who reduces your coverage for going non-panel, Income gives you the freedom to choose your specialist without reducing your annual limit.
- The Smart Trade-off: A slightly higher co-payment (7% panel / 10% non-panel) keeps premiums competitive, but your financial risk is tightly capped at $6,000 per policy year for panel treatments. This trade-off could save tens of thousands in cumulative premiums over your lifetime.
Why it wins: You accept a small increase in co-payment in exchange for significant long-term savings, while keeping your maximum out-of-pocket exposure tightly capped at $6,000 per policy year for panel treatments.
Although some benefits (i.e. pre- and post-hospitalisation coverage) are reduced when using non-panel providers, the same annual policy limit applies to both panel and non-panel treatments. This means you still have full flexibility in choosing where to seek treatment, without losing access to the overall level of annual coverage.
I’m interested in Enhanced IncomeShield Preferred + Essential Care rider
2. Best for Maximum Ceiling: HSBC Life Shield Plan A + Enhanced Care II rider
Ideal For: The planner who wants the highest possible financial ceiling for catastrophic illnesses, particularly high-cost cancer treatments.
- Industry-Leading Limits: HSBC Life stands out with its high $30,000 a month limit for non-CDL cancer drugs which is double the market average. This is also paired with a high $2.5 million annual limit for panel treatments. However, note that seeking treatment outside the panel will reduce the annual limit for this plan to $1 million.
- Guaranteed Cashless Access: HSBC backs its $2.5 million policy limit with a Letter of Guarantee (LOG). This ensures that even for massive bills, the hospital deals with the insurer directly, making the experience fuss free for you.
- Day-to-Day Perks: Immediate value through Value-Added Services (VAS) including $10 panel GP consultations and first standard consultation fee of $100 to specialist and extended panel, making high-quality everyday care accessible.
Why it wins: No other insurer currently offers $30,000 per month for non-CDL cancer drugs or backs a $2.5 million annual limit with a matching Letter of Guarantee.
Real-world scenario
Sarah, 45, is diagnosed with a non-CDL drug-treated cancer at $25,000 per month for 12 months ($300,000 total). With HSBC Plan A + Enhanced Care II at $30,000 per month, her treatment is covered in full. With a $15,000 per month rider she would face $120,000 in gaps. With a $5,000 per year rider, the gap balloons to $295,000.
I’m interested in HSBC Life Shield Plan A + Enhanced Care II rider
3. Best for Families: Enhanced IncomeShield Preferred + Optima Care rider
Ideal for: Parents with young children or individuals who want guaranteed access to the latest medical.
- Future-Proof Science: Income uniquely covers high-cost, non-MOH-approved CTGTP treatments up to $150,000 per lifetime — a meaningful benefit given how rapidly gene therapy is evolving. With the Optima Care rider, co-payment required is lower than the Essential Care rider option at 5% for panel and 8% for non-panel.
- Juvenile Perks: For those under 18, this combination includes a $50,000 lump sum payout if your child requires an ICU or HDU stay of 4 days or more. This cash benefit helps with costs insurance does not cover, such as a parent taking unpaid leave or arranging home nursing. You will receive an Autism Testing Benefit of up to $1,000 (with paediatrician referral, 10% co-payment required with benefit payable once per lifetime) on reimbursement basis.
- Consistency in Policy Limit: Income’s hidden strength is its consistent $1.5 million annual limit for both panel and non-panel providers. While other insurers "penalise" you with a lower cap for using non-panel doctors, Income maintains the same limit for both, offering true freedom of choice without penalising you for seeking a second opinion or using a specialist outside the network.
Why it wins: It provides the most robust "safety net" for non-MOH approved CTGTP treatments and severe paediatric emergencies.
Real-world scenario
Emily, 6, is admitted to ICU for 6 days with severe pneumonia. Beyond reimbursement of the medical bill itself, the policy pays a $50,000 lump sum to her parents which is then used to cover unpaid leave and post-hospital care. These are expenses that medical insurance typically do not reimburse.
I’m interested in Enhanced IncomeShield Preferred + Optima Care rider
4. The Lowest Premium Option: Raffles Shield Private + Choice rider
Ideal For: Those who wants a private hospital plan at the lowest possible cash outlay and is comfortable with tighter network restrictions.
- Competitive Price Point: This is the most affordable private Shield and rider combination in the Singapore market across nearly every age group, making private hospital coverage accessible on a tighter budget.
- The Trade-off: To achieve these premiums, the plan carries restrictions. Outpatient non-CDL cancer drugs are capped at just $5,000 per year (compared to $15,000 to $30,000 from other insurers). Additionally, the annual limit drops to a strict $600,000 if you use a non-panel doctor for treatment.
- Our Recommendation: This plan works best for those prepared for higher personal financial risk during a major illness, or who are confident staying strictly within the Raffles network. We also suggest adding the Raffles Cancer Guard rider to address the cancer drug coverage gap.
Why it wins: Raffles Shield Private plan gives you access to private hospital coverage for the lowest premiums, provided you are willing to stay within their doctor network.
I’m interested in Raffles Shield Private + Choice rider
5. Best for Rehabilitation: Singlife Shield Plan 1 + Health Plus Private rider
Ideal For: Those who prioritises long-term recovery support, already have (or plan to purchase) a Singlife CareShield or ElderShield, and value affordable premiums during peak working years
- Unmatched Recovery Support if you already have (or plan to purchase) a Singlife CareShield or ElderShield: Singlife stands out with a $20,000 lifetime Recovery Support benefit. This provides vital funding for home nursing and rehabilitation services (up to 730 days) if you require assistance with daily activities following a major medical event.
- The Balance: With Singlife Shield Plan 1, you get a $2 million annual limit at preferred providers and restructured hospitals with this reducing to a $1 million annual limit for non- providers. Premium-to-benefit ratio is particularly attractive for younger professionals.
- The Trade-off: Coverage for gene therapy (CTGTP) is limited to the MOH-approved list, and the non-CDL cancer drug limit of $10,000 per month is lower than competing plans. This combination may be best suited to those who are less concerned about these specific risk areas.
Why it wins: The ideal choice for those who believe healthcare does not end at the hospital exit. It provides the financial bridge for the long tail of recovery — rehabilitation and home care — where many plans leave a gap.
Real-world scenario
Robert, 65, suffers a major stroke that leaves him unable to dress, feed, or move without assistance. Because he holds Singlife Health Plus AND Singlife CareShield Plus, he is also certified for Severe Disability and unlocks $20,000 toward home nursing care over the next two years — funding that supplements his hospitalisation reimbursement.
I’m interested in Singlife Shield Plan 1 + Health Plus Private rider
Which plan is right for you?
|
If your priority is.. |
Consider this plan and rider combination |
|
I want sustainable premiums long-term |
Enhanced IncomeShield Preferred + Essential Care |
|
I need the highest cancer drug coverage |
HSBC Life Shield Plan A + Enhanced Care II |
|
I have young children or want CTGTP coverage |
Enhanced IncomeShield Preferred + Optima Care |
|
I want the lowest possible cash outlay |
Raffles Shield Private + Choice |
|
I value post-hospitalisation recovery support |
Singlife Shield Plan 1 + Health Plus Private |
At the end of the day, there is no one-size-fits-all plan in the 2026 insurance landscape. The best option depends on what you value most: long-term premium sustainability, access to the latest medical science, or the highest possible financial ceiling. Whether you are looking to protect an existing plan or explore new shield and rider options, the right choice requires weighing your personal risk profile, budget, and healthcare priorities.
Whether you are looking to protect your "Grandfathered" plans or want to explore the new shield and rider options available in 2026, we are here to help you navigate the fine print.
Limited time offer: Review your Shield Coverage
Still unsure which Shield Plan is right for you? Our in-house specialists are ready to help you review the fine print and find the right fit. Reach out to us using the button at the end of this article.
Plus, from now till 30 June 2026, review your Shield coverage and unlock:
- Up to $50 Cash Reward* 💵
- Up to 45% Commission Rebates^ on eligible plans
- Expert Guidance (Even if you don't have an agent!)
No agent? No problem. Let us be your agent and earn an extra $5 Reward* just for making the transfer. Transfer-in reward applicable for Income and Raffles Shield plans only.
*Terms and conditions can be found here.
Have a shield plan with a particular insurer? Read our shield plan updates here:
- General update on changes: Shield Plan and IP rider changes: This is your 2026 update
- Income: New IP Riders 2026: Should I switch to the new Enhanced IncomeShield riders?
- Raffles: A 2026 Update to your Raffles Shield plan and the new Raffles Choice Rider
- Singlife: Singlife Shield & Rider Changes (April 2026): Should You Switch to the New Rider?
- HSBC Life: HSBC Life Shield Plan and Rider: The 2026 Guide
|
Available Products on FSMOne Insurance |
|
Term Life, Whole Life, Critical Illness, Annuity, Health, Endowment, General Insurance (Personal and Commercial) from AIA, AIG, Allianz, China Taiping, Cigna, Chubb, Etiqa Insurance, FWD Insurance, Great Eastern, HSBC Life, Henner, Income, Manulife, MSIG, Raffles Health Insurance, Singlife, Sompo, Tokio Marine, and QBE. *Please check with our team if the product you want is available on FSMOne Insurance |
Information obtained from:
https://www.insurance.hsbc.com.sg/health/products/shield/
https://www.income.com.sg/health-insurance/enhanced-incomeshield
https://singlife.com/en/medical-insurance/shield
https://www.raffleshealthinsurance.com/products/raffles-shield/learn-more/raffles-shield-plans/
https://www.insurance.hsbc.com.sg/health/products/shield
Information retrieved on 27 April 2026.
Disclaimer:
^More information on our commission rebate program can be found here.
The views and opinions expressed in this article are solely our own and do not represent those of the insurer.
All materials and content found in this article are strictly for information purposes only and should not be considered as an offer or solicitation to transact in any product. This article is not a contract of insurance.
Insurance products are underwritten by the respective insurance partners and distributed by iFAST Financial Pte Ltd (“iFAST”). You are advised to review the specific terms, conditions and exclusions in the relevant policy contract.
You are advised to read the key product documents, including (but not limited to) the product summary, before deciding whether the product is suitable for you. You should consider carefully if the products you are purchasing are suitable for your financial objectives, experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of a product, please seek advice from a financial adviser before making a decision to purchase the product.
While iFAST and its third-party providers strive to provide
accurate and timely information, there may be inadvertent omissions,
inaccuracies, and typographical errors. Opinions expressed herein are subjected
to change without notice.
The comparisons and opinions provided are based on publicly
available data/information and are intended to provide a general overview of
the insurance products discussed. These comparisons do not cover all available
products and may not fully illustrate every aspect of the products discussed.
Purchasing a life insurance policy is a long-term commitment, and early termination may involve significant costs. The surrender value, if any, may be zero or less than the total premiums paid.
This advertisement has not been reviewed by the Monetary Authority of Singapore.
All materials and contents found in this site are strictly for general circulation and informational purposes only and should not be considered as an offer, or solicitation, to deal in any of the funds or products found/identified in this site. While iFAST Financial Pte Ltd ("IFPL") has tried to provide accurate and timely information, there may be inadvertent delays, omissions, technical or factual inaccuracies and typographical errors. Any opinion or estimate contained in this report is made on a general basis and neither IFPL nor any of its servants or agents have given any consideration to nor have they or any of them made any investigation of the investment objective, financial situation or particular need of any user or reader, any specific person or group of persons. You should consider carefully if the products you are going to purchase are suitable for your investment objective, investment experience, risk tolerance and other personal circumstances. If you are uncertain about the suitability of the investment product, please seek advice from a financial adviser, before making a decision to purchase the investment product. Past performance is not indicative of future performance. The value of the investment products and the income from them may fall as well as rise. Opinions expressed herein are subject to change without notice. In respect of any matters arising from, or in connection with the said research analyses or research reports, recipients of the report are to contact IFPL at 10 Collyer Quay, #26-01 Ocean Financial Centre Building, Singapore 049315, or by telephone at +65 6557 2853. Where the report contains research analyses or research reports from a foreign research house and if the recipient of such research analyses or research reports is not an accredited investor, expert investor, institutional investor or an ex-accredited investor, IFPL accepts legal responsibility for the contents of such analyses or reports to such persons only to the extent as required by law. Please note that only certain security(ies) herein are available to all investors, while the rest are only available for certain persons to invest in, such as Accredited Investors (as defined in the Securities and Futures Act) or one who invests at least S$200,000 (or its equivalent currency) per transaction. To qualify as an Accredited Investor, one needs to submit a declaration form and certain relevant supporting documents, according to iFAST’s prevailing policies and procedures.
Please read our full disclaimers on the website at ( https://secure.fundsupermart.com/fsmone/policies/328125/investment-account-terms-&-conditions).
iFAST Financial Pte Ltd (IFPL) (registered address: 10 Collyer Quay #26-01 Ocean Financial Centre Singapore 049315, Telephone: 6557 2000) holds the Financial Advisers Licence issued by the Monetary Authority of Singapore ('MAS') to conduct regulated activities of advising on securities, marketing of collective investment schemes and arranging of any contract of insurance in respect of life policies, other than a contract of reinsurance and the Capital Markets Services Licence issued by the MAS to conduct regulated activities of dealing in securities and providing custodial services for securities. While IFPL has made every effort to ensure the independence of the report's contents, IFPL's nature of business is such that IFPL and its connected and associated entities together with their respective directors, officers and staff may be involved in providing dealing or investment-related services in the abovementioned securities, and have taken or may take positions in the securities mentioned in this report, and may also act as the principal for any buy or sell trades.